在PACIFIC 中,sCRT 后的 Durvalumab 与 cCRT 后观察到的 durvalumab 具有相当的安全性,并且在较虚弱的人群中具有令人鼓舞的初步疗效。 SCI 9 September 2022 Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial (J Thorac Oncol IF:20.121) Garassino MC...
durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy (cCRT). Many patients are considered unsuitable for cCRT owing to concerns with tolerability. The phase 2 PACIFIC-6 trial (NCT03693300) evaluates the safety and ...
(PFS) and overall survival (OS) were better in the subgroup of patients administered durvalumab within 14 days after last radiation to randomization according to the PACIFIC study (Antonia SJ, etal. 2017, 2018 NEJM).Methods:This study was a prospective, single-arm, multicenter, phase II ...
单克隆抗体 别名 Durvalumab (Genetical Recombination)、Durvalumab (genetical recombination) (JAN)、Durvalumab (USAN/INN) + [10] 靶点 PDL1 作用机制 PDL1抑制剂(程序性死亡配体1抑制剂) 治疗领域 肿瘤消化系统疾病呼吸系统疾病+ [12] 在研适应症
比如在III期肺癌PACIFIC试验中大获成功的PD-L1抑制剂——Durvalumab(简称“I”药),治疗方案就是与放化疗的联合。 而从大局上来看,2011年第一种免疫检查点抑制剂(ICI),CTLA-4抑制剂——伊匹木单抗获批时,符合适应症的患者只占美国全...
1. https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-phase-iii-poseidon-trial-for-1st-line-treatment-of-stage-iv-non-small-cell-lung-cancer.html 2. Martinez P, Peters S, Stammers T, et al. Immunotherapy for the...
# if patients receive fewer than 4 cycles of platinum-based chemotherapy, the remaining cycles of tremelimumabactl (up to a total of 5) should be given after the platinum-based chemotherapy phase, in combination with IMFINZI, every 4 weeks. Þ optional pemetrexed therapy from week 12 until ...
3.2 PACIFIC study overview The PACIFIC study is a phase 3 study comparing consolidation durvalumab therapy with placebo in 713 patients with stage III NSCLC who did not experience disease progression after the induction platinum-based CRT. Patients randomly assigned to the experimental arm received 10...
然而,这项工作并未结束,只是为肺癌患者提供转化治疗的开始。Ⅲ期NSCLC不仅包含CRT的患者,还包括序贯放化疗的患者,但序贯放化疗的患者未纳入PACIFIC研究中。目前,在Ⅰ~Ⅲ期NSCLC中,阿斯利康还开展了多项研究,包括PACIFIC 2,PACIFIC 5,PACI...
More patients with stage III non–small cell lung cancer received sequential chemoradiation and delayed the time to durvalumab treatment in a real-world setting compared with those enrolled on the phase 3 PACIFIC trial.